Its possible that we get more deals replica watches like the one just announced. But we are not in it for pure OEM manufacturing, not at the moment anyway. You have mentioned omega replica in the past a $1Bn target by 2015. Going by the developments, you have successfully raised money, things look to be on track. What are the louis vuitton replica top 3 milestones/successes Opto Circuits is looking to achieve in that drive in the next 2-3 yearsis it -USFDA approval louis vuitton replica for DIOR/DES Stents (BMS stents are in the process) -large-scale rolex replica manufacturing for medical equipment biggies -dominating Indian market for Invasives? As we explained before louis vuitton replica Criticare revenues are set to double. The investments made in Criticare are beginning omega replica to show. We have a slew of products coming out. Opto Circuits now has a complete range of products for addressing the full needs of patient monitoring in all environments CCU, OT. We are cartier replica able to address opportunities which we earlier could not because of a limited range rolex replica are big worldwide tenders from bodies such as the WHO. Opto Circuits is one of the shortlisted vendors. In the louis vuitton replica coming 2 years the invasive products from EuroCor will be a big driver of growth. Opto Circuits is the first with CE omega replica approval for DIOR replica wallets (drug eluting balloon) and Magical stent+DIOR (which is a superior technology to the DES stent). Sales are dependent on clinical louis vuitton replica data from tests, acceptance with doctors rolex replica, there are major market development efforts/costs involved. More the tests data, the easier to find major acceptance, easier to sell. Competitors on this technology are atleast 2 years replica watches uk away from approval, so we are very hopeful that these may prove to be real disruptive products, as they offer louis vuitton replica significant benefits over existing technology.